Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2

Joining a function-enhanced Fc-portion of human IgG to the SARS-CoV-2 entry receptor ACE2 produces an antiviral decoy with strain transcending virus neutralizing activity. SARS-CoV-2 neutralization and Fc-effector functions of ACE2-Fc decoy proteins, formatted with or without the ACE2 collectrin domain, were optimized by Fc-modification. The different Fc-modifications resulted in distinct effects on neutralization and effector functions. H429Y, a point mutation outside the binding sites for FcγRs or complement caused non-covalent oligomerization of the ACE2-Fc decoy proteins, abrogated FcγR interaction and enhanced SARS-CoV-2 neutralization. Another Fc mutation, H429F did not improve virus neutralization but resulted in increased C5b-C9 fixation and transformed ACE2-Fc to a potent mediator of complement-dependent cytotoxicity (CDC) against SARS-CoV-2 spike (S) expressing cells. Furthermore, modification of the Fc-glycan enhanced cell activation via FcγRIIIa. These different immune profiles demonstrate the capacity of Fc-based agents to be engineered to optimize different mechanisms of protection for SARS-CoV-2 and potentially other viral pathogens.


Introduction
Recent history has seen regular deadly zoonotic coronavirus spillover events with the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 (1), Middle East respiratory syndrome (MERS) coronavirus in 2012 (2) and SARS-CoV-2 in December 2019 (3). SARS related coronaviruses are found in bats throughout Southeast Asia (4) and the serology of people living in proximity to a Rhinolophus spp bat colony suggests these zoonotic infections are not uncommon (5). Since the publication of the SARS-CoV-2 genome in January 2020 (3) there has been rapid development and deployment of vaccines for SARS-CoV-2 (6) and the clinical development of multiple SARS-CoV-2 spike specific neutralizing monoclonal antibodies (mAbs) from convalescent patients or animals, reviewed in (7).
Evolution of the SARS-COV-2 spike protein has selected for increased transmissibility, for example by increased affinity for host cells (8), with the emergence and then dominance of many new variants of concern (VOC) including Alpha, B.1.1.7; Beta, B.1.351; Gamma, P.1; Delta, B.1.617.2 (9) and most recently, Omicron, B.1.1.529 (WHO) that impact the neutralization efficacy of antibodies generated against the spike antigen of earlier strains (10). This includes profound escape from neutralization by some mAbs (11)(12)(13)(14)(15) and significant loss of neutralization activity of convalescent sera (13,16,17) and of humoral responses to first generation vaccines (12,18,19) reviewed in (10). Reinfection by neutralization-escape variants (20,21) and break-through infection in vaccinees is now a feature of the pandemic (13,19). Furthermore, protective antibody responses in humans are largely restricted to specific coronavirus species since few Abs to SARS-CoV-2 receptor binding domain (RBD) cross-neutralize SARS-CoV or MERS-CoV (22) but the recent identification of spike-specific broadly neutralizing mAbs may be a key to future pan-beta-coronavirus pandemic preparedness (23). Overall, despite increased surveillance and biosecurity (24) and the development of SARS-CoV-2 vaccines and mAbs, a critical vulnerability to variants of concern (VOC) and future pandemic novel coronaviruses persists. There is a need for prophylactic and therapeutic approaches that are more broadly effective against Sarbecoviruses.
We report the development of multifunctional antiviral proteins by applying novel mutations of the Fc and glycan modification to manipulate the Fc component of ACE2-Fc which resulted variously in increased virus neutralization, complement directed killing and activation of FcgRIIIa.

Materials and methods
Constructs and proteins -trACE2 and trACE2-Fc Truncated ACE2 (trACE2) comprised the catalytic portion of the ACE2 ectodomain and a sequence encoding trACE2 (aa 19-615, Accession BAB40370) in pHLsec (63) was a gift from Merlin Thomas (64). This trACE2 sequence was fused to a synthetic DNA for human IgG1 Fc (Accession AXN93652.1) in pcDNA3.4 (ThermoFisher) with an encoded linker sequence D 615 -GSGSGSG-T 223 , where D 615 is the last residue of ACE2 and T 223 (Eu numbering) is the fusion point to IgG1-Fc on the amino terminal side of the Fc core hinge containing the inter-heavy chain disulfides (for full amino acid sequences see Supplementary Text). -flACE2-Fc comprised the full-length ACE2 ectodomain fused to human IgG1-Fc. The incorporation of a synthetic DNA encoding the collectrin domain (GeneArt, ThermoFisher) formed a full length ACE2 ectodomain encoding sequence (aa 19-740) fused to the human IgG1-Fc via a linker with the sequence S 740 -GGGGS-T 223 , where S 740 is the last residue of ACE2 and T 223 is the fusion point to IgG1-Fc. EflACE2-Fc. EflACE2-Fc was equivalent to the flACE2-Fc, except it incorporated the three mutations, T27Y, L79T, N330Y reported as sACE2.v2.4 and having enhanced affinity for SARS-CoV-2 spike RBD (43). The EflACE2-Fc construct was a synthetic DNA (GeneArt) in pcDNA3.4 (ThermoFisher). The mutations H429F, H429Y and E430G in the Fc were introduced using cleavage at a unique Afe I (New England Biolabs) site within codons for E430-L432 and the insertion of appropriate mutagenic oligos with NEBuilder according to the manufacturer's instructions (NEB).
ACE2-Fc protein expression used transient transfection of Expi293 cells (Thermo Fisher Scientific). The supernatant of Expi293 transiently transfected for the expression of ACE2-Fc was extensively dialysed against 10mM TrisHCl pH 8 and applied to a High-Q column (BioRad Laboratories). Bound proteins were eluted with the indicated gradient to buffer A with 0.4 M NaCl and washed with 1 M NaCl. Fractions were examined by SDS-PAGE, fractions containing ACE2-Fc were pooled and concentrated using a 30 kDa cut-off filtration device (Merck) and separated by SEC using a Superose 6 column (GE Lifesciences). Lamelli native PAGE (150V, 2.5 h, 4°C), was performed according to (65).

Bio-layer interferometry
Measurements of the affinity of ACE2 proteins for S protein RBD (64) were performed on the Octet RED96e (ForteBio). All assays were performed at 25°C using anti-human IgG Fc capture (AHC) biosensor tips (ForteBio) in kinetics buffer (PBS pH 7.4 supplemented with 0.1% (w/v) BSA and 0.05% (v/v) Tween-20). After a 60 second (60s) biosensor baseline step, ACE2-Fc recombinant proteins (20 mg/mL) were loaded onto the AHC sensors by submerging sensor tips for 200s and then washing in kinetics buffer for 60s. For most ACE2-Fc recombinant proteins, association measurements were performed by dipping into a two-fold dilution series of SARS-CoV-2 spike RBD (64) from 16-250 or 500nM for 180s and dissociation was measured in kinetics buffer for 180s. For EflACE2-Fc WT a two-fold dilution series of 2 -31 or 63nM was used. Sensor tips were regenerated five times using a cycle of 5s in 10 mM glycine pH 1.5 and 5 s in kinetics buffer. Baseline drift was corrected by subtracting the average shift of an ACE2-Fc-loaded sensor not incubated with SARS-CoV-2 spike RBD, and an unloaded sensor incubated with SARS-CoV-2 spike RBD. Curve fitting analysis was performed with Octet Data Analysis 10.0 software using a global fit 1:1 model to determine K D values and kinetic parameters. Curves that could not be fitted were excluded from the analyses.

ACE2-Fc and dimeric recombinant soluble (rs) FcgR binding by flow cytometry
The ACE2-Fc proteins or the anti-CD20 mAb, Rituximab, at 5µg/ml, or the indicated concentrations were incubated with Ramos cells expressing transfected spike proteins (Ramos-S cells) (67) at 5x10 6 cells/ml in 25µl in fluorescence activated cell sorting (FACS) buffer-PBS containing 0.5% (w/v) BSA, 1mM glucose (PBS/BSA/G), for 30 min on ice. Cells were washed twice with FACS-buffer, incubated with APC conjugated anti-human IgG-Fc for thirty minutes on ice, washed again and resuspended in 25 µl of FACS-buffer.
Evaluation of the binding of dimeric rsFcgR was performed as described in (68). ACE2-Fc opsonized Ramos-S cells were resuspended in 0.5µg/ml of dimeric rsFcgRIIIa (V158 form) or FACS-buffer and incubated for 30 min on ice followed by 1/500 streptavidin-APC (or anti-hIgG-Fc labelled with fluorescein isothiocyanate for confirmation of ACE2-Fc opsonization) for 20 min on ice. The cells were washed, resuspended in FACS buffer and analyzed on a Canto II flow cytometer (Becton Dickinson).

Complement fixation immunoassay for ACE2-Fc
Ninety-six well flat-bottom MaxiSorp Nunc plates (ThermoFischer Scientific) were coated with 5 mg/ml Avidin in PBS overnight, blocked, and then incubated with either two-fold dilution of biotinylated RBD (69) or 2.5 mg/ml in 0.1% casein for 1 hour at RT. The ACE2-Fc proteins were then added over the indicated concentration range. In experiments to measure C5b-C9 fixation, the plates were incubated with 10% fresh human serum for 30 minutes at RT followed by 1/2000 dilution of rabbit anti-C5b-C9 (Millipore) for 1 hour at RT, washed and then incubated with goat anti-rabbit IgG conjugated to HRP (Millipore) at 1/2000 dilution for 1 hour at RT, followed by TMB substrate for 15-20 minutes at RT (70). Reactivity was stopped using 1 M sulfuric acid and absorbance was measured at 450 nm. Test samples and reagents were prepared in PBS 0.1% (w/v) casein and plates washed thrice between each step using PBS, 0.05% (v/v) Tween 20. Samples were tested in duplicate and corrected for background reactivity using negative control wells from which ACE2-Fc proteins were omitted. The mean and SEM from independent experiments are shown.

Complement dependent cytotoxicity
CDC was measured by opsonizing Ramos-S cells as above (5x10 6 cells/ml in 25µl in PBS/BSA/G for 30 min on ice) before resuspending in 1/3 diluted normal human serum for 30 min at 37°C. Cells were washed twice with PBS and the dead cells were enumerated by staining with 1/500 Zombie green (BioLegend) before fixing with 2% paraformaldehyde in PBS and analysis on a Canto II flow cytometer.

Modelling of ACE2-Fc decoy proteins
Alphafold v2.2 (73, 74) was run on the EflACE2-Fc sequence using five models and specifying two homo-oligomers. The output of this recapitulated the observed structure of the ACE2 homodimer (PDB ID: 6M17, ACE2 residues 19-729) with an RMSD of 1.378 Å, however, the IgG1-Fc domains did not pair. The IgG1-Fc plus the G4S linker and collectrin domain of ACE2 (residues 615-729) was therefore run on Alphafold v2.2 specifying two homo-oligomers and an output of five models. Of these, one model showed correctly paired IgG1 Fc domains and a collectrin domain folded as in the full-length ACE2 structure (PDB ID: 6M17) with an RMSD of 0.718 Å. Superimposition of the collectrin domains of the model with the ACE2 homodimer and that with the paired IgG1-Fc allowed reconstruction for the complete EflACE2-Fc sequence. Positioning of the linkers was manually modelled based on the human B12 IgG crystal structure (PDB ID: 1HZH) to allow the correct pairing of the Fc-hinge disulphide residues at positions 749 and 752 ( Figures 1A, B). The trACE2-Fc structure was modelled manually on the EflACE2-Fc model, maintaining the relative position of the ACE2 catalytic domains as in the full-length homodimer. Coordinate files are available from the authors on request.
Docking of the SARS-CoV-2 spike RBD to the EflACE2-Fc construct was modelled using HADDOCK v2.4 (75,76) and the best model from the top scoring cluster was taken, having a HADDOCK score of -151 ± 4.2 and an RMSD from the overall lowest energy structure of 0.7 Å ± 0.5 ( Figure 1E). The SARS-CoV-2 spike RBD and ACE2 catalytic domain (residues 19-614) had an overall RMSD of 2.733 Å from the observed SARS-CoV-2 binding to native ACE2 (PDB ID: 6M0J), with the SARS-CoV-2 and ACE2 chains aligning more closely with RMSDs of 0.400 Å and 1.400 Å respectively. A HADDOCK SARS-CoV-2 spike RBD docking model generated using an Alphafold prediction of the native ACE2 structure aligned similarly with the observed structure (PDB ID: 6M0J) with an RMSD of 2.940 Å, and overlayed the EflACE2-Fc structure with an RMSD of 0.573 Å.
Data and Statistical analysis used the Prism software package (GraphPad Software 9.0.2, San Diego, CA). Curve fitting to agonist(inhibitor) response curves for EC 50 (IC 50 ) determination and ANOVA with multiple comparisons tests were used as indicated in the Figure legends.

Results
A series of ACE2-Fc fusion proteins (Table 1) were produced and analyzed for improved capacity to neutralize SARS-CoV-2 infection and to enhance or transform Fc-dependent effector functions attributed normally to the mechanisms of action of antibodies. Three versions of the ACE2 ectodomain were fused to the human IgG1 Fc portion. The first ACE2 fusion comprised the full length ACE2 ectodomain (flACE2-Fc, aa 19-740), including both the catalytic and collectrin domains ( Figure 1A) and the second, an enhanced full length ACE2 ectodomain, EflACE2-Fc, with enhanced binding to SARS-CoV-2 S protein-RBD resulting from three amino acid mutations in the RBD binding site of the ACE2 protein (T27Y, L79T and N330Y) (43) and the third comprised a truncated ectodomain (trACE2-Fc, aa 19-615) containing the ACE2 catalytic domain but lacking the collectrin domain. Models of the trACE2-Fc ( Figures 1C, D) and EflACE2-Fc ( Figures 1A, B) decoy proteins were generated using Alphafold 2 (73, 74) and EflACE2-Fc was docked to SARS-CoV-2 spike RBD ( Figure 1E). A comparison of the RBD docked to the Alphafold prediction of the EflACE2 and native ACE2 structures aligned similarly with the observed structure (PDB ID: 6M0J) with an RMSD of 2.733 Å and 2.940 Å respectively, and overlayed the RBD-EflACE2-Fc docked structure with an RMSD of 0.573 Å. This indicates that the affinity enhancing mutations do not impact the docking position of the SARS-CoV-2 spike RBD using this modelling approach. To evaluate the interaction with trimeric spike and assess the relative distance between ACE2 catalytic domains and adjacent RBD, the EflACE2-Fc-SARS-CoV-2 spike RBD or the trACE2-Fc-SARS-CoV-2 spike RBD model was overlayed on the RBD of chain A of the observed Spike-ACE2 complex structure (PDB ID: 7VXM) (Figures 1F, G). This showed that the ACE2 dimer in the EflACE2-Fc construct is not able to bind adjacent RBD on a single spike trimer due to distance restraints. Though the two ACE2 catalytic domains in the trACE2-Fc construct are likely not dimeric, through the lack of a collectrin domain (36), restraints imposed by disulphide bonding at the N-terminus of the Fc similarly act to restrict the distance between the ACE2 domains and likely also prevent binding to adjacent RBD for this construct ( Figure 1G).
The key rationale for the development of a ACE2 decoy antiviral protein as a biosecurity agent against a future pandemic is the presumption it will similarly inhibit SARS-CoV-2 variants and ACE2 tropic coronaviruses generally. Indeed, using an ELISA flACE2-Fc bound near equally to both the ancestral RBD and RBD from the beta, gamma and delta VOCs ( Figure 1H).
The activity of ACE2-Fc against SARS-CoV-2 variants was further addressed using a bead array. The inhibition of binding of biotinylated trACE2-Fc to an established array of 24 SARS-CoV-2 spike RBD variants (71) by unlabeled ACE2-Fc decoys was examined. Inhibition of binding to RBD-WT followed the hierarchy trACE2-Fc-WT < flACE2-Fc-WT < EflACE2-Fc-WT (IC 50 = 114, 80, 10 nM respectively) with effective inhibition of binding to all the individual RBD variants reached, with IC 50 values within two-fold of that observed with the ancestral RBD ( Figure 2). Thus, across the array of RBD variants the average IC 50 values (110 ± 4; 86 ± 4 nM; 9.5 ± 0.9 nM) simply replicated this hierarchy of increasing neutralization potency over trACE2-Fc-WT as variants with increased affinity for ACE2 have equivalent increased susceptibility to inhibition by ACE2, including the N439K, S477N and E484K RBDs and other variants associated with escape from neutralizing antibodies (11,54,77). This contrasted sharply with the neutralizing mAb S35 where binding to the L455F and A475V RBD variants was abrogated. Furthermore, the decoy proteins were also effective inhibitors of binding to the spike proteins of the SARS and NL63 beta-coronaviruses (Figure 2). This illustrates the intrinsic resistance of ACE2 based antiviral decoys to escape by spike mutation and their applicability to other viruses that also use ACE2 for entry.
In addition to fusion to wild-type (WT) IgG1-Fc, these ACE2 formats were also fused to a Fc carrying novel substitutions of histidine 429 (Eu numbering) with phenylalanine (H429F) or tyrosine (H429Y), or in the adjacent residue, a known IgG hexamerising mutation E430G (78,79). A glycan-modified form of trACE2-Fc was also produced in the presence of the mannosidase inhibitor kifunensine (trACE2-Fckif). The recombinant ACE2-Fc fusion proteins were purified first by anion exchange followed by size exclusion chromatography (SEC) and comprised largely a single species Native PAGE (N-PAGE) analysis showed that ACE2-Fc WT fusion proteins migrate as a single species, at~260 kDa for trACE2-Fc and at > 260 kDa for the flACE2-Fc and EflACE2-Fc fusion proteins, reflecting the additional presence of the collectrin domain ( Figure 3G). Notably the ACE2-Fc-H429Y variants (e.g. trACE2-Fc-H429Y Fc, Figure 3G, 5 th trACE2-Fc lane "Y") migrated in N-PAGE as several distinct higher molecular weight oligomer species, that were not apparent in denaturing SDS-PAGE, i.e. these comprise non-covalent oligomers. N-PAGE shift analysis showed that the normal and enhanced ACE2 (e.g. trACE2-Fc and EflACE2-Fc) proteins, and the Fc mutants, had high-specific binding activity for SARS-CoV-2 spike RBD, visualized by their shift to high molecular weight complexes following interaction with SARS-CoV-2 spike RBD-Ig (RBD-Ig "+" lanes, Figure 3G). When quantified by ELISA the ACE2-Fc proteins bound the bivalent ligand RBD-Ig with subnanomolar avidity and were unaffected by mutation of the Fc, excepting the oligomer forming H429Y Fc mutants which exhibited weaker binding ( Figure 3H).
The antiviral activities of the ACE2-Fc fusion proteins were determined in a microneutralization assay using SARS-CoV-2 infection of Vero cells (64) where the EC 50 endpoint corresponds to neutralization of~99% of the inoculum virions (66). The SARS-CoV-2 neutralization endpoint (EC 50 2.70 µM) of the unfused truncated ectodomain (trACE2 alone) was improved 10-fold by its fusion with the unmodified wildtype Fc region of IgG1 (trACE2-Fc-WT, EC 50 283 nM), consistent with its improved binding avidity ( Figure 4A). In accord with its increased intrinsic affinity for the RBD (Figure 3F), the EflACE2-Fc-WT (EC 50 11 nM) was a further~11 and 25-fold more inhibitory than the unmodified flACE2-Fc-WT (EC 50 124 nM) and trACE2-Fc-WT respectively (Figures 4A-C). Thus overall, EflACE2-Fc-WT ( Figure 4C) was~240-fold more active in virus neutralization than trACE2 alone ( Figure 4A). Of the five Fc modifications, the oligomeric (og) form of the H429Y Fc mutants fused with any ACE2 format, consistently displayed superior neutralization activity within its ACE2 format class. Thus, the oligomeric trACE2-Fc-H429Y og, isolated by SEC, had a neutralization activity (EC 50 21.9 nM) that was 13-fold improved over the monomeric trACE2-Fc-WT (EC 50 283nM, Figure 4A). Similarly, flACE2-Fc-H429Y og (EC 50 10.0 nM) showed greater potency than flACE2-Fc-WT (EC 50 124 nM) ( Figure 4B). Indeed, it was equivalent in neutralization activity to the EflACE2-Fc WT neutralization (EC 50 10.6 nM). Finally, the most potent inhibitor, EflACE2-Fc-H429Y og (EC 50 4.23 nM) ( Figure 4C), was~600-fold more active than the monovalent trACE2 ( Figure 4A). This improved neutralization by the H429Y decoy contrasted with the H429F and the E430G modifications which did not significantly alter SARS-CoV-2 neutralization Human ACE2-Fc decoy proteins broadly inhibit binding to RBD variants and S from variants and related Sarbecoviruses. Biotinylated trACE2-Fc was incubated with a concentration series of unlabelled trACE2-Fc, flACE2-Fc, EflACE2-Fc fusion proteins or the inhibitory human mAb S35. Binding to RBD or S proteins coupled to beads was determined. Apparent IC50 (nM) values are indicated. NB, no binding. activity in any ACE2-Fc format (Figures 4A-C). As a comparator the laboratory equivalent of the therapeutic mAb REGN 10933 (casirivimab) had an EC 50 of 3.6 nM, (n = 2).
The Fc receptors of leukocytes and serum complement provide the two major effector systems harnessed normally by the Fc portion of antibodies. FcgR functions, which may include ADCC, phagocytosis and clearance of opsonized viruses are important antiviral effector mechanisms and are increasingly found to play a protective role during SARS-CoV-2 infection (57,58,60,61,80,81). The interaction of FcgRIIIa with the ACE2-Fc fusion proteins was evaluated by flow cytometry using Ramos cells expressing SARS-CoV-2 spike protein (Ramos-S cells)  Figure S1A). The loss of FcgRIIIa binding was not due to lack of opsonization of the Ramos-S cells by the H429Y variants as all ACE2-Fc proteins showed similar binding of the SARS-CoV-2 spike protein on the cell surface (Table 2).
Next, FcgRIIIa activation by ACE2-Fc fusion proteins was evaluated as a validated surrogate of ADCC (67). FcgRIIIa was activated by Ramos-S cells opsonized with a Fc-WT fusion of any ACE2 format ( Figure 5A). The flACE2-Fc-WT induced FcgRIIIamediated activation of the reporter cell at 2.7-fold lower concentration than the trACE2-Fc-WT (EC 50 1.7 nM) ( Figure 4A, p < 0.0001, Supplementary Figures S1B, C), indicating that inclusion of the ACE2 collectrin domain, improved FcgRIIIa activation. Notably, the increased affinity of the EflACE2-Fc WT for SARS-CoV-2 spike protein, did not increase FcgRIIIa activation above that of flACE2-Fc WT ( Figure 5A). However, the most potent FcgRIIIa activation was achieved following glycan-modification by kifunensine (82) during the production of the trACE2-Fc. Thus, despite the lower activity of the trACE2-Fc format, FcgRIIIa activation by trACE2-Fc-kif exceeded that of the flACE2-Fc and EflACE2-Fc and approached that of the therapeutic anti-CD20 mAb rituximab used as a comparator on the CD20 + Ramos-S cells ( Figure 5A; Supplementary Figure S1B). Thus, the hierarchy of FcgRIII activation by the proteins was trACE2-Fc-kif > EflACE2-Fc WT~flACE2-Fc-WT > trACE2-Fc-WT.
In accord with the FcgRIIIa binding data (Supplementary Figure  S1A), modification of ACE2-Fc decoys by the H429F or E430G mutation had only modest effects on FcgRIIIa activation ( Figure 5A; Supplementary Figures S1B, C). In contrast, the H429Y mutation in all ACE2-Fc formats ablated FcgRIIIa activation of cells which is consistent with their abrogated binding to FcgRIIIa (Supplementary Figure S1A). Thus, while enhancing virus neutralization, the H429Y modified Fc in trACE2-Fc, flACE2-Fc and EflACE2-Fc formats were largely inactive in FcgR binding and consequently unable to activate cells via FcgRIIIa ( Figure 5A).  The second major Fc-dependent effector system is the classical complement pathway. The activation of complement by the ACE2-Fc proteins was tested initially by ELISA for the capacity to fix complement components C5b-9 and then to mediate complementdependent killing of cells expressing SARS-CoV-2 spike protein.
The fixing of C5b-9 (Supplementary Figure S1D) which forms the membrane attack complex, was achieved by all Fc fusions but was enhanced by both the H429F Fc mutation and the hexamerising E430G mutation of trACE2-Fc compared to unmodified Fc-WT. Despite the H429Y mutated Fc preforming oligomers, which might be anticipated to confer superior complement fixation, this was not apparent and the trACE2-Fc-H429Y oligomer form, showed similar C5b-9 fixation as the trACE2-Fc-WT and glycomodifed trACE2-Fc-kif, (Supplementary Figure S1D).
Despite the ELISA showing that the trACE2-Fc-WT fusions with an unmodified Fc fix C5b-9, analysis of cell killing showed that the unmodified Fc-WT fusion proteins of any ACE2 format failed to mediate significant CDC ( Figure 5B). In stark contrast to this CDC inactivity, both the H429F and the hexamerising E430G Fc mutants of trACE2-Fc fusion proteins were remarkably active in mediating complement lysis of Ramos-S cells ( Figure 5B). The monomeric form of trACE2-Fc-H429Y mn was active, although substantially less potent than the H429F mutant. H429 in the Fc is thus a site for modification that remarkably potentiates the Fc's capacity for stimulating complement-mediated target lysis.

Discussion
In this study we examined different antiviral functions of ACE2-Fc virus decoy proteins. As in IgG antibodies, the Fc- region drives the effector responses mediated by the IgG-Fc fusion proteins. In vivo SARS-CoV-2 challenge models (57-61) have found Fc immune functions of antibodies decreased virus load, spread from nasal tissue to major organ systems, cytokine storm and inflammation, and mortality. In contrast, ablating Fc function resulted in increased disease severity or mortality (58)(59)(60)83).
Recently a non-neutralizing human mAb with Fc-enhanced ADCC activity conferred partial protection in a SARS-CoV-2 infection model and contributed to complete protection in combination with a neutralizing mAb (80). Indeed, ADCC potency is an indicator of humoral responses that protect against severe disease in humans (81). While complement activation features in the pathophysiology of severe COVID-19 it is likely to be initially protective (84) and is an identified function of anti-SARS-CoV-2 therapeutic antibodies (85). The Fc portion is thus an important element to optimize for the development of ACE2-Fc as an anti-SARS-CoV-2 antiviral molecule and for viral entry receptors fused to Fc more generally. Hence, we have manipulated three major antiviral activities of ACE2-Fc by modifying its Fc portion to enhance the existing decoy (neutralization) action of the ACE2 component, complement mediated killing and activation of FcgR. Firstly, the H429Y mutation, in the Fc CH3 domain outside the Fcg receptor or complement contact sites of the CH2 domain, resulted in the formation of oligomers of the decoy protein which resulted in improved neutralization potency. The improved neutralization activity and oligomeric nature of the H429Y Fc mutant decoys mimic the polymeric antibody classes, IgA (86) and IgM (87) where avidity contributes to the efficacy of SARS-CoV-2 neutralization. Fc : Fc interactions are a recognized property of IgG antibodies (88) and their stabilization by mutation can lead to the formation of in solution oligomers (89). In contrast, the E430G modification of IgG is known to promote "on-target" oligomerization (hexamerization) of IgG (79), but did not significantly alter SARS-CoV-2 neutralization activity in any ACE2-Fc format. In contrast, the H429Y Fc mutation enhanced neutralization potency of all formats of the ACE2-Fc decoy proteins. H429Y Fc mutation in combination with the inclusion of the collectrin domain and the triple ACE2 mutations enhancing affinity for S (43), (i.e. EflACE2-Fc-H429Y) resulted in an overall 600-fold increased SARS-CoV-2 neutralization potency over that of the monomeric truncated ACE2 domain. The neutralization potency of EflACE2-Fc-H429Y (4.2 nM) was comparable to that of the laboratory equivalent of the therapeutic mAb REGN 10933 (casirivimab, 3.6 nM). A feature of the H429Y mutation was the loss of binding by FcgRIIIa. Mutations at the CH2/CH3 interface can affect low affinity FcgR binding to the Fc (90), suggesting these sites, though distant, can affect each other (91).
Secondly, the phenylalanine substitution of histidine 429 (H429F) of the ACE2-Fc proteins did not enhance neutralization but did transform CDC against S expressing targets. This improved CDC activity was like that of E430G mutated ACE2-Fc, a known "on-target" Fc-hexamerising mutation, a format optimal for C1 binding and activation (78,79). Lastly, FcgR potency of trACE2-Fc was improved by modifying the Fc glycan (82) to enhance FcgRIII binding (92). It is likely that similar treatment of flACE2-Fc WT and EflACE2-Fc WT, or alternatively, amino acid substitution to increase affinity for FcgRIIIa (93), would similarly further improve their FcgRIII activating potency. Notably, FcgRIII activation was a little reduced for the decoy lacking the collection domain, indicating the formatting of Fc-fusion proteins can impact Fcmediated activity.
We have demonstrated ACE2-Fc to be a potent agent against SARS-CoV-2, not only for neutralization but also for the harnessing of Fc-mediated effector functions. The exemplar Fc modifications demonstrated herein illustrate the potential for the tuning of Fc function to optimize virus neutralization, FcgR interaction and complement activation. This selection of desired functional profiles could aid the deployment of broadly effective ACE2-Fc, mAbs and other Fc therapeutics. There has been a rapid progression of multiple different SARS-CoV-2 mAbs to clinical use that is likely to herald increased deployment of mAbs clinically for infectious diseases. The optimization of Fc functions will make a significant difference to their clinical success. Furthermore, the world remains susceptible to new pandemics and vaccine escape variants. Thus, an antiviral decoy comprising optimized Fc fusion to a viral entry receptor such as ACE2-Fc, is an important option for deploying a rapid first line of defense to contain new zoonotic viral threats while vaccines, mAbs and antiviral drugs are being developed.

Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. PDB coordinate files are available from the authors on request.